eligibility_summary
Eligibility: Adults (≥18) with ARID1A‑mutated endometrial cancer, measurable disease, ≥1 prior chemo, prior PD‑1/PD‑L1 therapy (≤50% may lack). ECOG 0–2, tumor tissue available, adequate labs, not pregnant, contraception required. Exclude recent chemo/RT, unresolved ≥G2 AEs, other trials, severe hypersensitivity, active/uncontrolled infection (controlled HIV/HBV/HCV OK), need for immunosuppression, transplants, serious GI/cardiac/psychiatric disease, QTc>470, vaccines except inactivated, PPIs/strong CYP3A4/1A2, herbal supplements, controlled brain mets allowed.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm trial of avelumab plus M1774 in ARID1A-mutated recurrent endometrial cancer. Avelumab: human IgG1 monoclonal antibody immune-checkpoint inhibitor targeting PD-L1, blocks PD-L1/PD-1 signaling to restore anti-tumor T-cell activity and can engage Fc-mediated ADCC by NK cells against PD-L1–positive tumor cells. M1774 (tuvusertib): oral small-molecule ATR kinase inhibitor, suppresses the DNA-damage response/replication-stress checkpoint, driving tumor cell death with expected synthetic lethality in ARID1A-deficient tumors. Targeted cells/pathways: PD-1/PD-L1 axis on tumor and immune cells (T cells, NK cells) and the ATR-mediated DNA damage response in ARID1A-LOF tumor cells.